Barclays analysts initiated coverage on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a Overweight rating on January 28, 2026. Alnylam Pharmaceuticals, Inc.
Barclays analysts initiated coverage on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a Overweight rating on January 28, 2026.
Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $346.79 with a market capitalization of $54.5B.
Current market data
NASDAQ · ALNY
$255.96
Down: -$0.60 · -0.23%
Live quote updated
Keep reading
analyst ·
analyst ·
analyst ·
sec_filing ·
